TACR1 and neuroblastoma: Encouraged by recent observations of antitumor effects of tachykinin receptor antagonists in various cancer cell lines, we investigated the role of TACR1 in high-risk neuroblastoma and explored whether targeting TACR1 could be a therapeutic option in this disease.